Compare NP & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NP | TARS |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | 58 | N/A |
| Industry | Specialty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | N/A | 2020 |
| Metric | NP | TARS |
|---|---|---|
| Price | $24.47 | $70.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 6 |
| Target Price | $27.04 | ★ $89.00 |
| AVG Volume (30 Days) | 325.5K | ★ 409.6K |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $25.45 | $55.67 |
| Revenue Next Year | $15.74 | $30.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $14.78 | $38.51 |
| 52 Week High | $31.75 | $85.25 |
| Indicator | NP | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 62.48 | 54.02 |
| Support Level | $24.29 | $65.62 |
| Resistance Level | $26.85 | $78.34 |
| Average True Range (ATR) | 1.42 | 3.04 |
| MACD | 0.37 | 0.25 |
| Stochastic Oscillator | 91.47 | 81.80 |
Neptune Insurance Holdings Inc is a high-growth, data-driven MGA that is revolutionizing the way homeowners and businesses protect against the growing risks of flooding. It offers a range of easy-to-purchase residential and commercial insurance products - including primary flood insurance, excess flood insurance, and parametric earthquake insurance - distributed through a nationwide network of agencies. It underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies, whom the company refer to as capacity providers, that manage both this risk and the associated claims handling.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.